<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03238833</url>
  </required_header>
  <id_info>
    <org_study_id>VGHKS15-CT11-12</org_study_id>
    <nct_id>NCT03238833</nct_id>
  </id_info>
  <brief_title>Poor Ovarian Responders Undergoing IVF Using Luteal Ovarian Stimulation Versus Follicular Ovarian Stimulation</brief_title>
  <official_title>Department of Obstetrics and Gynecology, Kaohsiung Veterans General Hospital</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kaohsiung Veterans General Hospital.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kaohsiung Veterans General Hospital.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators attempted to compare the clinical outcomes and cumulus genes expression in
      poor ovarian responders undergoing luteal ovarian stimulation or follicular ovarian
      stimulation in in vitro fertilization cycles.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multiple follicular wave theory proposed by Baerwald et al. implied that follicle recruitment
      may occur in the luteal phase of menstrual cycle. Therefore, luteal phase ovarian stimulation
      (LPOS) was considered as a potential feasible stimulation method during in vitro
      fertilization (IVF) cycle. In the beginning, in order to avoid delaying cancer treatment,
      LPOS was applied for fertility preservation of cancer patients, showing no difference in
      numbers of oocyte retrieved, mature oocytes and fertilization rate between luteal or
      follicular phase stimulation. In the recent, LPOS was used for infertility women, suggesting
      that LPOS owned quite good IVF outcomes. In previous studies, premature luteinizing hormone
      (LH) surge, a major reason worsening ovarian quality in poor ovarian responders (PORs), was
      seldom found in LPOS. High progesterone in luteal phase may aid in suppressing premature LH
      surge. An updated research claimed that numbers of oocyte retrieved, mature oocytes and
      fertilized oocytes in LPOS significantly increased when compared to follicular ovarian
      stimulation. Therefore, the investigators presumed that LPOS was a more effective method than
      follicular stimulation in PORs.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 3, 2017</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>oocytes and embryos</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>retrieved oocytes in number</description>
  </primary_outcome>
  <primary_outcome>
    <measure>oocytes and embryos</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>matured oocytes in number</description>
  </primary_outcome>
  <primary_outcome>
    <measure>oocytes and embryos</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>fertilized oocytes in number</description>
  </primary_outcome>
  <primary_outcome>
    <measure>oocytes and embryos</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>day 3 embryos in number</description>
  </primary_outcome>
  <primary_outcome>
    <measure>oocytes and embryos</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>top-quality day 3 embryos in number</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>pregnancy rate</measure>
    <time_frame>Pregnancy will be confirmed 4 weeks after embryo transfer.</time_frame>
    <description>Clinical pregnancy rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>genes expression</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>cumulus cells genes expression</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Fertilization in Vitro</condition>
  <arm_group>
    <arm_group_label>luteal ovarian stimulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The controlled ovarian stimulation in in vitro fertilization cycle was started since luteal phase.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>follicular ovarian stimulation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The controlled ovarian stimulation in in vitro fertilization cycle was started since early follicular phase phase.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>luteal ovarian stimulation</intervention_name>
    <description>In the in vitro fertilization cycle, controlled ovarian stimulation was started since the luteal phase.</description>
    <arm_group_label>luteal ovarian stimulation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>follicular ovarian stimulation</intervention_name>
    <description>In the in vitro fertilization cycle, controlled ovarian stimulation was started since the follicular phase.</description>
    <arm_group_label>follicular ovarian stimulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Poor ovarian responders (PORs) met the Bologna criteria, having at least two of the
             three following features:

               1. advanced maternal age (≥ 40 years) or any other risk factor for POR,

               2. a previous POR (≤ 3 oocytes with a conventional stimulation protocol), and

               3. an abnormal ovarian reserve test. An abnormal ovarian reserve test was defined as
                  antral follicle count (AFC) &lt; 5 or anti-Müllerian hormone (AMH) &lt; 1 ng/mL in this
                  study.

        Moreover, two episodes of a previous POR after maximal stimulation alone would be
        sufficient to define a patient as a POR.

        Exclusion Criteria:

          -  oophorectomy

          -  exposure to cytotoxic or pelvic irradiation for malignancy

          -  taking herbal drugs or other hormonal agents
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kuan-Hao Tsui, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Kaohsiung Veterans General Hospital.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Salvatore Giovanni Vitale, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Messina</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Li-Te Lin, PhD</last_name>
    <phone>+886-7-3422121</phone>
    <phone_ext>4012</phone_ext>
    <email>litelin1982@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kaohsiung Veterans General Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <zip>81362</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kuan-Hao Tsui, PhD</last_name>
      <phone>+886-7-3422121</phone>
      <phone_ext>4014</phone_ext>
      <email>khtsui60@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Li-Te Lin, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Salvatore Giovanni Vitale, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <reference>
    <citation>Baerwald AR, Adams GP, Pierson RA. A new model for ovarian follicular development during the human menstrual cycle. Fertil Steril. 2003 Jul;80(1):116-22.</citation>
    <PMID>12849812</PMID>
  </reference>
  <reference>
    <citation>Baerwald AR, Adams GP, Pierson RA. Ovarian antral folliculogenesis during the human menstrual cycle: a review. Hum Reprod Update. 2012 Jan-Feb;18(1):73-91. doi: 10.1093/humupd/dmr039. Epub 2011 Nov 8. Review.</citation>
    <PMID>22068695</PMID>
  </reference>
  <results_reference>
    <citation>Bedoschi GM, de Albuquerque FO, Ferriani RA, Navarro PA. Ovarian stimulation during the luteal phase for fertility preservation of cancer patients: case reports and review of the literature. J Assist Reprod Genet. 2010 Aug;27(8):491-4. doi: 10.1007/s10815-010-9429-0. Epub 2010 May 9. Review.</citation>
    <PMID>20455017</PMID>
  </results_reference>
  <results_reference>
    <citation>von Wolff M, Thaler CJ, Frambach T, Zeeb C, Lawrenz B, Popovici RM, Strowitzki T. Ovarian stimulation to cryopreserve fertilized oocytes in cancer patients can be started in the luteal phase. Fertil Steril. 2009 Oct;92(4):1360-5. doi: 10.1016/j.fertnstert.2008.08.011. Epub 2008 Oct 18.</citation>
    <PMID>18930226</PMID>
  </results_reference>
  <results_reference>
    <citation>Maman E, Meirow D, Brengauz M, Raanani H, Dor J, Hourvitz A. Luteal phase oocyte retrieval and in vitro maturation is an optional procedure for urgent fertility preservation. Fertil Steril. 2011 Jan;95(1):64-7. doi: 10.1016/j.fertnstert.2010.06.064. Epub 2010 Aug 5.</citation>
    <PMID>20688325</PMID>
  </results_reference>
  <results_reference>
    <citation>Cakmak H, Rosen MP. Ovarian stimulation in cancer patients. Fertil Steril. 2013 May;99(6):1476-84. doi: 10.1016/j.fertnstert.2013.03.029. Review.</citation>
    <PMID>23635348</PMID>
  </results_reference>
  <results_reference>
    <citation>Cakmak H, Katz A, Cedars MI, Rosen MP. Effective method for emergency fertility preservation: random-start controlled ovarian stimulation. Fertil Steril. 2013 Dec;100(6):1673-80. doi: 10.1016/j.fertnstert.2013.07.1992. Epub 2013 Aug 26.</citation>
    <PMID>23987516</PMID>
  </results_reference>
  <results_reference>
    <citation>Kuang Y, Hong Q, Chen Q, Lyu Q, Ai A, Fu Y, Shoham Z. Luteal-phase ovarian stimulation is feasible for producing competent oocytes in women undergoing in vitro fertilization/intracytoplasmic sperm injection treatment, with optimal pregnancy outcomes in frozen-thawed embryo transfer cycles. Fertil Steril. 2014 Jan;101(1):105-11. doi: 10.1016/j.fertnstert.2013.09.007. Epub 2013 Oct 23.</citation>
    <PMID>24161646</PMID>
  </results_reference>
  <results_reference>
    <citation>Martínez F, Clua E, Devesa M, Rodríguez I, Arroyo G, González C, Solé M, Tur R, Coroleu B, Barri PN. Comparison of starting ovarian stimulation on day 2 versus day 15 of the menstrual cycle in the same oocyte donor and pregnancy rates among the corresponding recipients of vitrified oocytes. Fertil Steril. 2014 Nov;102(5):1307-11. doi: 10.1016/j.fertnstert.2014.07.741. Epub 2014 Aug 22.</citation>
    <PMID>25154677</PMID>
  </results_reference>
  <results_reference>
    <citation>Kuang Y, Chen Q, Hong Q, Lyu Q, Ai A, Fu Y, Shoham Z. Double stimulations during the follicular and luteal phases of poor responders in IVF/ICSI programmes (Shanghai protocol). Reprod Biomed Online. 2014 Dec;29(6):684-91. doi: 10.1016/j.rbmo.2014.08.009. Epub 2014 Sep 6.</citation>
    <PMID>25444501</PMID>
  </results_reference>
  <results_reference>
    <citation>Li Y, Yang W, Chen X, Li L, Zhang Q, Yang D. Comparison between follicular stimulation and luteal stimulation protocols with clomiphene and HMG in women with poor ovarian response. Gynecol Endocrinol. 2016;32(1):74-7. doi: 10.3109/09513590.2015.1081683. Epub 2015 Sep 15.</citation>
    <PMID>26370530</PMID>
  </results_reference>
  <results_reference>
    <citation>Wei LH, Ma WH, Tang N, Wei JH. Luteal-phase ovarian stimulation is a feasible method for poor ovarian responders undergoing in vitro fertilization/intracytoplasmic sperm injection-embryo transfer treatment compared to a GnRH antagonist protocol: A retrospective study. Taiwan J Obstet Gynecol. 2016 Feb;55(1):50-4. doi: 10.1016/j.tjog.2015.07.001.</citation>
    <PMID>26927248</PMID>
  </results_reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 27, 2017</study_first_submitted>
  <study_first_submitted_qc>July 31, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 3, 2017</study_first_posted>
  <last_update_submitted>January 13, 2018</last_update_submitted>
  <last_update_submitted_qc>January 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kaohsiung Veterans General Hospital.</investigator_affiliation>
    <investigator_full_name>Li-Te Lin</investigator_full_name>
    <investigator_title>Department of Obstetrics and Gynecology</investigator_title>
  </responsible_party>
  <keyword>In vitro fertilization</keyword>
  <keyword>Poor ovarian responder</keyword>
  <keyword>Luteal ovarian stimulation</keyword>
  <keyword>Antagonist protocol</keyword>
  <keyword>Cumulus cells</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

